A – normal cell division, B – cancer cell division; 1 – apoptosis; 2 – damaged cell. From the National Cancer Institute. Photo credit: Wikipedia)
The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.
“It is still too premature to estimate when a clinical trial will open to further test this drug combination therapy, but we are now in the planning phase and encouraged by the results of these laboratory experiments,” says Andrew Poklepovic, M.D., oncologist and member of the Developmental Therapeutics research program at VCU Massey Cancer Center and assistant professor in the Division of Hematology, Oncology and Palliative Care at VCU School of Medicine. “We are also encouraged by the fact that the drugs used in this therapy are either already approved by the FDA to treat certain cancers or are currently being investigated in other clinical trials.”
Featured in the journal Molecular Pharmacology, the study led by Paul Dent, Ph.D., demonstrated that the drugs sorafenib and regorafenib synergize with a class of drugs known as PI3K/AKT inhibitors to kill a variety of cancers. Sorafenib and regorafenib work by blocking the production of enzymes called kinases, which are vital to the growth and survival of cancer cells. Sorafenib is currently approved by the FDA to treat kidney and liver cancers, and regorafenib is currently approved for the treatment of colorectal cancer. However, sorafenib and regorafenib do not directly affect PI3K and AKT kinases, which are also very active in promoting cancer cell survival. The addition of a PI3K/AKT inhibitor to the combination of sorafenib and regorafenib dramatically increased cell death and was even effective against cells with certain mutations that make one or the other drug less effective.
“We know that there are certain cellular processes that are frequently dysregulated in cancers and important to cell proliferation and survival, but if you shut down one, then cells can often compensate by relying on another,” says Dent, Universal Corporation Distinguished Professor for Cancer Cell Signaling and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as vice chair of the Department of Neurosurgery at VCU School of Medicine. “We are blocking several of these survival pathways, and the cancer cells are literally digesting themselves in an effort to stay alive.”
Read more . . .
The Latest on: Drug combination therapy
Drug combination may become new standard treatment for advanced kidney cancer - Science Daily
February 17, 2019 - Drug combination may become new standard treatment for advanced kidney cancer Science DailyA combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney ...
EC Approves BMS Leukemia Drug in Pediatric Combination Therapy - Pharmaceutical Technology Magazine
February 15, 2019 - EC Approves BMS Leukemia Drug in Pediatric Combination Therapy Pharmaceutical Technology MagazineOn Feb. 11, 2019, Bristol-Myers Squibb (BMS) announced that it received approval from the European Commission for Sprycel (dasatinib) in combination with ...
Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma - Cancer Therapy Advisor
February 15, 2019 - Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Cancer Therapy AdvisorCombined treatment with pembrolizumab and axitinib is superior to sunitinib alone as first-line therapy for locally advanced or metastatic renal cell carcinoma ...
Combination treatment, diabetes drug and immunotherapy, may help to fight breast cancer - Medical Xpress
February 6, 2019 - Combination treatment, diabetes drug and immunotherapy, may help to fight breast cancer Medical XpressResearchers in Finland have discovered a drug combination that collaborates with the cancer cell oncoprotein MYC, which, in large quantities, causes ...
Calithera Looks To Combination Therapies To Tackle Cancer - Seeking Alpha
February 19, 2019 - Calithera Looks To Combination Therapies To Tackle Cancer Seeking AlphaCalithera Biosciences is evaluating its oncology drug CB-839 in two combination studies using already approved drugs to treat patients with renal cell ...
FDA Expands Drug's Label With Combo Therapy for First-Line NSCLC Treatment - Pharmacy Times
February 1, 2019 - FDA Expands Drug's Label With Combo Therapy for First-Line NSCLC Treatment Pharmacy TimesOfficials with the FDA have expanded the label of pemetrexed for injection (Alimta, Eli Lilly) in combination with pembrolizumab (Keytruda, Merck) and platinum ...
Drug Combination Could be New Step in Fighting Breast Cancer - Specialty Pharmacy Times
February 21, 2019 - Drug Combination Could be New Step in Fighting Breast Cancer Specialty Pharmacy TimesTranslational study of breast cancer therapy sought to 'taking research from bench to bedside.'
Newly Approved Drug Combination Improves Survival for People with Peripheral T Cell Lymphoma - On Cancer - Memorial Sloan Kettering
February 8, 2019 - Newly Approved Drug Combination Improves Survival for People with Peripheral T Cell Lymphoma On Cancer - Memorial Sloan KetteringA recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.
Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients - PRNewswire
February 18, 2019 - Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients PRNewswireSUZHOU, China, Feb. 17, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, ...
Combination drug therapy may offer new hope to kidney cancer victims, study says - International Business Times, Singapore Edition
February 19, 2019 - Combination drug therapy may offer new hope to kidney cancer victims, study says International Business Times, Singapore EditionA new research conducted by an investigator at the Dana-Farber Cancer Institute has found that a combination of two drugs, one of them being an ...
Combination Drug Therapies vs Monotherapies for Low Back Pain, Sciatica: A Review - Clinical Pain Advisor
February 5, 2019 - Combination Drug Therapies vs Monotherapies for Low Back Pain, Sciatica: A Review Clinical Pain AdvisorThere is insufficient evidence supporting improved efficacy of combination drug therapy vs monotherapy in the management of low back pain and sciatica, ...
Combination therapy may halt the progression of neuroblastoma in children - Drug Target Review
February 4, 2019 - Combination therapy may halt the progression of neuroblastoma in children Drug Target ReviewResearchers have uncovered a crucial link between polyamines and MYCN, revealing that the polyamine pathway is entirely regulated by the MYCN oncogene.